IGC
IGC Pharma, Inc.
Next earnings Aug 12, 2026 · consensus $-0.02 EPS, $248K rev
$0.26
▲ +0.42%$0.26▼ -15.16%
over 1Y
L $0.25EODHDH $0.47
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.4%
1W-1.4%
1M-9.3%
3M+1.2%
YTD-9.3%
1Y-15.2%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Buy
Conservative balance sheet (liabilities/equity 0.38x); but revenue declined -5.5% YoY.
Revenue (FY2025) $1.27M · FY2025
IGC Pharma, Inc. shows $1.27M in FY2025 revenue (-5.5% YoY), a -560.3% net margin, and -112.5% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $898K | $397K | $911K | $1.34M | $1.27M |
| Gross profit | $113K | $194K | $442K | $733K | $619K |
| Operating income | -$8.72M | -$15.4M | -$11.6M | -$9.80M | -$7.45M |
| Net income | -$8.81M | -$15.0M | -$11.5M | -$13.0M | -$7.12M |
| Diluted EPS | — | — | — | -$0.22 | -$0.09 |
| Net margin | -981.2% | -3782.4% | -1263.0% | -966.5% | -560.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$21.8M
EV / EBITDA—
EV / Sales17.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-32.3%
FCF yield-22.2%
Quality & risk
ROIC (est.)-91.0%
Free cash flow-$4.91M
Total debt$137K
Net cash$268K
Altman Z-Score-16.42 distress
Piotroski F-Score3/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+10.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Material agreement2026-06-08
- 10-Q Quarterly report2026-05-15
- 8-K Material agreement2026-04-20
- 8-K Other event2026-03-30
- 8-K Material agreement2026-03-12
- 8-K Material agreement2026-01-06
- 8-K Charter / bylaws change2026-01-02
- S-3/A Shelf registration (potential raise)2025-12-03
- S-3 Shelf registration (potential raise)2025-11-17
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-052026-06-08open ↗10-QPeriod ending 2026-03-312026-05-15open ↗8-KPeriod ending 2026-04-142026-04-20open ↗4Period ending 2026-04-012026-04-06open ↗4Period ending 2026-04-012026-04-06open ↗4Period ending 2026-04-012026-04-06open ↗4Period ending 2026-04-012026-04-06open ↗8-KPeriod ending 2026-03-302026-03-30open ↗10-KTPeriod ending 2025-12-312026-03-18open ↗8-KPeriod ending 2026-03-062026-03-12open ↗4Period ending 2026-02-032026-02-04open ↗4Period ending 2026-01-192026-01-20open ↗
Frequently asked
- Is IGC Pharma, Inc. (IGC) a buy?
- IGC currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.38x); but revenue declined -5.5% YoY.
- What is IGC Pharma, Inc.'s quality score?
- IGC scores 41.50980392156862/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001326205, latest 10-Q filed 2026-05-15) · EODHD · as of 6/22/2026, 9:48:22 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.